BAA toxwp 118/CTP-2022-112800 -evaluate and promote the use of cell- and tissue-based assays that more accurately represent human susceptibility than animal models to adverse reactions and predict…
Ended Definitive Contract Awarded Last action
- Contract number
- 75F40122C00146
- Awardee
-
Georgia TECH Research Corp UEI EMW9FC8J3HN4
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $2,014,369
Award facts
- Opportunity
-
- FY22 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Solicitation · FDABAA2200123 · Posted Nov 10, 2021
- Contract value 100% obligated
- $2,014,369.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 165 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $2,014,369 |
About this award
This is a $2,014,369 Firm Fixed Price definitive contract awarded by the Food and Drug Administration (FDA) to the Georgia TECH Research Corp, a non-profit research organization associated with the Georgia Institute of Technology. The contract is a no-cost extension for an ongoing research project titled "In Vitro Assessment of Chemical Mixture-Induced Airway Inflammation in Healthy and Diseased Lungs".
The research aims to evaluate and promote the use of cell- and tissue-based assays that better represent human susceptibility to adverse reactions compared to animal models. Key tasks include developing high-throughput in vitro air-blood barrier assays to determine dose-response curves and benchmark doses for e-cigarette constituents and mixtures. Subcontractors include Emory University and the Wisconsin Corp For Biomedical Research.
This contract was awarded as part of the FDA's Broad Agency Announcement for regulatory science research and development, which does not use set-aside designations. The research is focused on advancing tools, standards, and approaches to support the FDA's mission of ensuring the safety, efficacy, and quality of regulated products.
Description
BAA toxwp 118/CTP-2022-112800 -evaluate and promote the use of cell- and tissue-based assays that more accurately represent human susceptibility than animal models to adverse reactions and predict threshold of toxicological concerns resulting from EX
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Emory University | $360,356 | |
| Wisconsin Corp For Biomedical Research | $384,838 |
Quick answers
Who was awarded contract 75F40122C00146?
75F40122C00146 was awarded to Georgia TECH Research Corp by Food and Drug Administration (Department of Health and Human Services) on September 28, 2022.
How much is contract 75F40122C00146 worth?
The government has obligated $2,014,369 on 75F40122C00146.
Was contract 75F40122C00146 competed?
The extent of competition for 75F40122C00146 was full and open competition. The government received 165 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award